Shortly after initiation, SGLT2 inhibitors were associated with approximately twice the risk of diabetic ketoacidosis as were DPP4 inhibitors, although cases of diabetic ketoacidosis leading to hospitalization were infrequent (NEJM)
Diabetes News
Tag: SGLT2 inhibitor
Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
Despite improvements in glucose control and reduction in body weight, therapy with dapagliflozin exerted no significant effect on HDL cholesterol levels and HDL functionality (Cardiovascular Diabetology)
Sodium Glucose Cotransporter 2 Inhibition in the Diabetic Kidney
The findings expand and refine our understanding of SGLT2 and its inhibition, have relevance for clinical practice, and will help interpret ongoing clinical trials on the long-term safety and cardiovascular effects of SGLT2 inhibitors (Medscape) – Registration required
The renal threshold for glucose re-absorption predicts diabetes improvement by sodium glucose co-transporter 2 inhibitor therapy
These findings indicate that patients who have higher renal threshold for glucose re-absorption can be expected to more effectively respond to SGLT2 inhibitor therapy in terms of lowering HbA1c level (Journal of Diabetes Investigation)
This site complies with the 